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doi:10.1016/j.ejvs.2009.02.010Abstract Objective: The objective of this study was to summarise data about endovascular
stent-graft placement for patients with type B aortic dissection (type B-AD) in China.
Methods: All published series in Chinese on endovascular stent-graft placement for type B-AD
from 1999 through 2008 were identified. Thirty-five studies, involving a total of 1498 patients,
were included in this review.
Results: Procedure success was reported in 89.4 1.7% of the patients. Overall complications
were reported in 16.6 1.2% of the patients. Major complications were reported in 1.7 0.2%,
with neurological complications in 0.5 0.1%. In-hospital mortality was 2.0 0.4%. The mean
follow-up was 24.0 16.1 months.
Conclusion: Endovascular stent-graft placement is technically feasible with high procedure
success and relatively low complication rate in selected patient groups with type B-AD. Both
short- and mid-term outcomes appear to be favourable.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Successful stent grafting of patients with acute type B
aortic dissection (B-AD) was first reported by Dake and
colleagues1 in 1999; Nienaber and colleagues2 simulta-
neously reported their results in patients with sub-acute
and chronic type B-AD. Eggebrecht et al.3 performed
a meta-analysis of stenting for aortic dissections with
descending tears and showed a procedure success in 98.2%,
stroke in 1.9% and paraplegia in 0.8% of the patients. Wang
et al.4 and Jing et al.5 independently published the13922231628; fax: þ86 020
hoo.com.cn (G.-qi Chang).
ty for Vascular Surgery. Publishepreliminary experience of endovascular stent-graft place-
ment for type B-AD patients in China in 1999. Later, many
studies have been published in Chinese-language publica-
tions. This article summarises all the data currently avail-
able about endovascular stent-graft placement for patients
with type B-AD in China.
Materials and Methods
Data sources
With the search phrases ‘aortic dissection’ and ‘stent
graft’ or ‘endovascular’, a comprehensive search of thed by Elsevier Ltd. All rights reserved.
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and January 2008 was performed using the China National
Knowledge Infrastructure database to identify all studies on
endovascular stent-graft treatment for patients with type
B-AD. A multistage assessment was used to include the
qualified articles. At the first stage, only abstracts were
reviewed. Only the articles focussing on endovascular stent-
graft placement for patients (n 10) with type B-AD were
included for data extraction. At the second stage, the full
articles were reviewed; only the articles with sufficient data
(40% of pre-defined variables) and follow-up longer than
1 month for each survival case were included. In the case of
multiple reports of previously listed patients from a single
center, only the articles with the most recent number of
patients or with most information were included.
Definitions
Aortic dissection (AD) was classified according to the
Stanford classification. It was considered acute if occurring
within the first 14 days from onset of symptoms and chronic
if it exceeded beyond that. The intervention indications for
acute dissections were as follows: (1) persistent back/chest
pain, (2) uncontrollable hypertension, (3) malperfusion
syndrome, (4) rupture and (5) a maximal aortic diameter
5 cm. The indications for chronic dissections were: (1)
psuedo-aneurysm with diameter 5 cm or rapid enlarge-
ment >5 mm per year and (2) acute symptoms. Complica-
tions were defined as major when life threatening or
necessitating emergent management (e.g., stroke, access
arterial damage) whereas minor ones were defined as those
that may recover later without further aggressive treat-
ment (e.g., infection of the access site). Procedure success
was defined as complete coverage of the primary entry tear
without a type I or III endoleak at the end of the procedure.
Persistent endoleak was defined as one that still existed at
the latest follow-up.
Data extraction
A standardised protocol for data extraction including 53
pre-defined variables regarding clinical characteristics,
procedural data, in-hospital and follow-up data was intro-
duced by Eggebrecht.3 A modified standardised protocol
including 47 pre-defined variables (six variables were
deleted from the standardised protocol because only a few
articles had mentioned them) was used to analyse each
article in this review. Extraction of data was performed
independently by the authors. Mutual consensus was ach-
ieved by further discussion when discrepancies occurred.
Unspecified information was classified as not available
(n.a); thus the number of patients (denominator) varied
with the specific variables. For the studies without the
required data for survival analysis, we managed to contact
the corresponding authors or the first authors for supple-
mentary materials about survival outcome.
Statistical analysis
The number of events divided by the number of treated
patients with available data was used to calculate theindividual rates of events. In order to avoid potential
underestimation of events owing to the differing patient
numbers, a worst-case model was calculated for some
variables with important clinical impact. This model
assumes that all reported, but unspecified, events occurred
in dissection patients and provides a worst case of the
rates. Results were presented as mean 1 standard devi-
ation or median and range. Two-sided chi-square test for
categorical variables and two-sided Student’s t-test for
continuous variable were used to compare between
patients with acute and chronic type B-AD. The Kaplane
Meier non-parametric method was used to estimate the
mortality, and compared using the log-rank test. A P-value
<0.05 was considered statistically significant. Statistical
software SPSS 13.0 was used for all the statistical analysis
mentioned earlier.
Results
Studies overview
Thirty-five studies, involving a total of 1498 patients, were
included in this study. For some variables only a small
proportion of the data were available. General information
of these studies was overviewed (Table 1).
Procedural and in-hospital data
Procedure success of 89.4 1.7% was achieved. Emergent
surgical conversion was required in 0.2 0.1% of patients
(Table 1). In-hospital complications were reported in
15.2 1.1% of patients (worst-case estimate: 14.5 1.1%)
(Tables 2 and 3). Major complications were 0.8 0.2%
(worst-case estimate: 0.8 0.1%), whereas minor compli-
cations were reported as 14.2 1.1% (worst-case estimate:
13.5 1.1%). Procedure-related complications were
1.3 0.5%, with retrograde type A-AD 0.1 0.03% and
access complications 1.2 0.5%. As shown in Table 2, 1.1
stents were used per patient, with Talent (Medtronic, USA)
as the most commonly used stent graft (Table 4). The
neurological complications were 0.3 0.1% (worst-case
estimate: 0.3 0.1%); of these patients, 0.3 0.1%
suffered a stroke (worst-case estimate: 0.3 0.1%). Para-
plegia was not reported during hospitalization. Thirty of
1437 patients died during the in-hospital period, and the
overall in-hospital mortality was 2.1 0.4% (worst-case
estimate: 2.0 0.4%), with rupture of the dissection as the
leading cause of death (Table 5). Two additional deaths
occurred within the 30-day period, yielding a 30-day
mortality of 2.2 0.4%.
Overstenting of aortic branches
Intentional overstenting of left subclavian artery (LSA)
without re-vascularisation was conducted in 88 patients
among 1166 patients whose data were available (7.5%).
Most of these patients tolerated the procedure well, except
for three patients: one death each due to brain stem
ischaemia (1.1%) and cerebral infarction (1.1%) and another
suffered from mild left subclavian steal syndrome (LSSS)
(1.1%), another underwent transient left extremity
Table 1 Detailed overview of the analyzed report
Author Year Patients
with AD
(n)
Proc.
Success
(n)a
Emergency
conversion
(n)
Overall
complications
(n)
Major
complications
(n)
Post-
operative
endoleak
(n)
Overall
neurologic
complications
(n)
Paraplegia
(n)
30-day
mortality
(n)
Post-discharge
surgical
conversion (n)
Aortic
Rupture
during
follow-up (n)
Post-discharge
mortality
during
follow-up (n)
Jing6 2003 146 139 1 31 2 6 0 0 6 2 0 2
Zhang 7 2003 44 34 0 11 1 10 1 0 2 0 0 1
Wu8 2004 15 15 0 0 0 0 0 0 0 0 0 0
Zhang9 2004 10 8 0 n.a. 0 0 n.a. 0 1 0 0 0
Li10 2004 11 9 0 n.a. 0 2 0 0 0 0 0 0
Shi11 2005 150 122 0 n.a. 2 26 1 0 1 n.a. n.a. n.a
Ling12 2005 26 22 0 n.a. n.a. 4 n.a. 0 0 n.a. n.a. 0
Zhang13 2005 12 11 0 n.a. 0 1 n.a. 0 1 n.a. n.a 0
Guo14 2005 159 n.a. 0 n.a. 0 n.a. 0 0 6 0 0 n.a
Shan15 2005 24 21 0 n.a. 1 2 n.a. n.a. 1 1 0 0
Su16 2005 22 n.a. 0 n.a. 0 n.a. 0 0 1 n.a. 0 0
Luo17 2006 22 22 1 1 1 0 0 0 0 0 0 0
Adil hasan18 2006 25 22 0 4 1 2 0 0 1 0 0 0
Li19 2006 39 39 0 n.a. n.a. 0 n.a. n.a. 0 0 0 0
Zhao20 2006 15 14 0 n.a. n.a. 1 n.a. n.a. 0 0 0 0
Tan21 2006 15 15 0 n.a. n.a. 0 n.a. 0 3 0 0 0
Qian22 2006 20 20 0 n.a. 0 0 n.a. 0 0 n.a. 0 0
Lu23 2006 17 17 0 n.a. n.a. 0 n.a. n.a. 0 0 0 0
Li24 2006 17 15 0 n.a. 1 2 n.a. 0 n.a. 0 0 0
Yu25 2006 180 161 0 18 0 18 0 0 2 0 1 1
Wang26 2006 11 11 0 0 0 0 0 0 0 0 0 0
Luo27 2006 55 45 0 10 1 9 0 0 1 0 0 0
Pang28 2006 12 12 0 3 0 0 0 0 0 0 0 0
Chang29 2007 121 112 0 23 9 9 3 0 3 0 2 4
Sheng30 2007 18 16 0 2 0 2 n.a. 0 0 0 0 0
Zhang31 2007 17 17 0 n.a. n.a. 0 n.a. 0 1 n.a. n.a. 0
Yang32 2007 43 38 0 7 0 5 0 0 0 0 0 0
Wang33 2007 36 32 0 13 0 4 0 0 2 0 0 0
Dong34 2007 10 n.a. 0 n.a. n.a. n.a. n.a. n.a. 0 n.a. n.a. 0
Luo35 2007 16 15 0 n.a. n.a. 0 n.a. 0 0 n.a. 0 0
Zhang36 2007 19 19 0 0 0 0 0 0 0 0 0 0
Dai37 2007 61 n.a. 1 n.a. n.a. n.a. n.a. 0 n.a. n.a. 0 n.a
Yang38 2007 48 46 0 1 0 1 0 0 0 0 1 1
Jing39 2007 50 44 0 16 2 6 1 1 0 1 2 3
Zhu40 2007 12 1 0 n.a. n.a. 11 n.a. n.a. 0 n.a. n.a. 0
All 1498 1114/1246
89.4 1.7%
3/1498
0.2 0.1%
140/845
16.6 1.2%
21/1270
1.7 0.2%
121/1246
9.7 1.7%
6/1187
0.5 0.1%
1/1396
0.1 0.04%
32/1420
2.3 0.4%
4/1152
0.3 0.1%
6/1271
0.5 0.1%
12/1128
1.1 0.1%
a Some studies just provided the number of endoleaks without classification. Considering that the case of endoleak type II or IV is rare, it
was assumed that all the endoleaks were type I or III.
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Table 2 In-hospital data
Data available
(n)
Number of events
or cases (n%)
Procedure success 1246 1114 (89.4 1.7%)
Number of stent-grafts
per patient
309 1.1
Adjunctive endovascular
procedures
795 4 (0.5 0.2%)
Overall complications
(In-hospital)
988 150 (15.2 1.1%)
Major complications 1212 10 (0.8 0.2%)
Minor complications 998 140 (14.2 1.1%)
Procedure-related
complications
1301 17 (1.3 0.5%)
Retrograde type A-AD 1456 2 (0.1 0.03%)
Access complications 1321 16 (1.2 0.5%)
Neurologic complications 1205 4 (0.3 0.1%)
Stroke 1244 4 (0.3 0.1%)
Paraplegia 1411 0
In-hospital mortality 1437 30 (2.0 0.4%)
In-hospital mortality,
procedure related
1498 9 (0.6 0.2%)
In-hospital mortality,
non-procedure related
1498 22 (1.5 0.4%)
30-Day mortality 1498 32 (2.2 0.4%)
Table 3 Worst-case estimates
Data available
(n)
Number of events
or cases (n%)
Overall in-hospital
complications
1034 150 (14.5 1.1%)
Major complications
during hospitalization
1279 10 (0.8 0.1%)
Minor complications
during hospitalization
1034 140 (13.5 1.1%)
Neurologic complications
during hospitalization
1270 4 (0.3 0.1%)
Stroke 1312 4 (0.3 0.1%)
In-hospital mortality 1507 30 (2.0 0.4%)
Additional late mortality
over 1e72 m
801 7 (0.9 0.1%)
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(1.1%), and one experienced mild weakness of the left
upper extremity (1.1%). The overall percentage of patients
who had a complication because of the intentional over-
stenting without re-vascularisation was 5.7% (5 of 88). Re-
vascularisation of LSA prior to overstenting was carried out
for 14 patients among 1166 patients (1.2%), consisting of
left common carotid artery (LCCA)eLSA bypass for six
patients, LCCAeleft vertebral artery bypass for four, right
subclavian arteryeLSA bypass for two patients, and
unknown method of bypass for two. RCCAeLCCAeLSA
bypass prior to overstenting of LSA and LCCA was carried
out for one patient. Incident overstenting of LSA and LCCATable 4 Types of stents
The types
of stents
The number
of institutes (n)a
T
o
Talent (Medtronic, USA) 17 3
Hercules & Aegis (MicroPort,
PRC)
10 1
Ankura II (Lifetech, PRC) 5 1
Zenith (Cook, USA) 3 6
Yuhengjia (Yuhengjia, PRC) 3 n
Vasoflow (Vascore, PRC) 2 1
Endofit (Endomed, USA) 2 5
Welltech (Welltech, PRC) 2 n
Griking (Grikin, PRC) 1 n
Unknown homemade bands 7 1
a One institute may use more than one kind of stent grafts. Informa
b It is a sum up of available numbers, as only 12 institutes reportedhappened in one patient, which was managed by emergent
ascending aortaeLCCAeLSA bypass. Intentional over-
stenting of celiac axis with prior abdominal aortaecommon
hepatic arteryesuperior mesentery artery bypass was
carried out for two patients. Incident overstenting of celiac
axis was not reported. For all the cases with re-vascular-
isation of the overstenting aortic branches, no over-
stenting-related complications were reported.
Follow-up data
Fourteen studies, including 641 patients, provided the
mean follow-up period of 24.0 16.1 months. False lumen
thrombosis was reported in 84.2 1.6% of the patients
(Table 6). In 0.5 0.04% of the patients, post-discharge
surgical conversion was needed. Post-discharge complica-
tions were reported in 3.1 0.8% of the patients and post-
discharge mortality was 0.8 0.1%. Persistent endoleak
occurred in 1.5 0.3% of the patients, nine of which,
according to the data available, were type I endoleaks.
Stent migration was observed in 0.4 0.2% of the patients.
In the survival analysis, 225 patients with detailed survival
data were included. The cumulative survival rates werehe number
f stents (n)b
The diameter
of the stent (mm)
The length
of the covered
stent (mm)
48 30e40 100e150
23 30e44 40e160
9 30e40 100e160
28e38 77e150
.a. 24e44 60e130
4 n.a. n.a.
n.a. n.a.
.a. n.a. 35e100
.a. 28e36 130e150
7 n.a. n.a.
tion about the type of stent grafts were absent in 8 institutes.
the exact number of stent grafts used.
Table 5 Causes of in-hospital death
Causes Number (n) Rate (%)
Rupture of the dissection 8 26.7
Ischemia-reperfusion injury 3 10
Cardiac tamponade 2 6.7
Cerebral embolism 2 6.7
Pulmonary infection 2 6.7
Toxic shock 2 6.7
Myocardial infarction 1 3.3
Ischemia of brain stem 1 3.3
Renal failure 1 3.3
Cardiac arrest 1 3.3
Cardiac arrhythmia 1 3.3
Mesenteric artery embolism 1 3.3
Cerebral hemorrhage 1 3.3
Unknown reason 3 10
Data not available 1 3.3
All 30 100
Figure 1 Kaplan-Meier estimate of overall survival.
650 G.-qi Chang, Z.-lun Li97.3 1.1% at 30 days, 94.8 1.5% at 1 year, 93.9 1.8% at
2 years and 91.2 2.6% at 3 years, respectively (Fig. 1).
Acute versus chronic dissection
Of the total 35 studies, 18 specified whether stent-graft
placement was carried out for acute or chronic type B-AD
(Table 7). For the overall complications, major complica-
tions, minor complications, procedure-related complica-
tions, stroke, paraplegia or 30-day mortality, there was no
significant difference between the acute and chronic groups.
Discussion
Although dramatic improvement in operative techniques,
anesthesiological methods, and medical therapy has been
made in recent years, type B-AD still remains a challengingTable 6 Follow-up data after stent-graft placement
Data available
(n)
Number of
events (n)
Duration of follow-up
(months)
641 24.0 16.1
False lumen thrombosis 431 363 (84.2 1.6%)
Post-discharge surgical
conversion
416 2 (0.5 0.04%)
Adjunctive endovascular
procedures
419 3 (0.7 0.2%)
Post-discharge
complications
508 16 (3.1 0.8%)
Post-discharge mortality 830 7 (0.8 0.1%)
Persistent endoleak 660 10 (1.5 0.3%)
Emerging aortic
dissection
740 5 (0.7 0.4%)
Stent migration 451 2 (0.4 0.2%)
Post-discharge
retrograde type A-AD
738 3 (0.4 0.1%)problem for vascular surgeons. Endovascular stent-graft
placement for type B-AD has achieved encouraging short-
and mid-term outcomes widely. Our study summarised all
the data on endovascular stent-graft placement for type
B-AD currently available in China. The in-hospital mortality
was 2.1 0.4%. Because of incomparability of patients,
these early mortality rates cannot be compared with the
results of open surgery. Surgical mortality ranging from
6.1% to 14% have been reported in two largest cardiovas-
cular centres in China.41,42
Neurological deficits are the most devastating compli-
cations of open repair for type B-AD. The International
Registry of Acute Aortic Dissection investigators43 reported
neurological deficits in 23.2% of the patients treated by
traditional surgery, with cerebrovascular accident in 9.0%
and paraplegia in 4.5%, respectively. The paraplegia rates
for endovascular treatment of aortic dissections were
reported much lower as 0.8% in the EUROSTAR trial.44 In our
study, no paraplegia occurred during hospitalization and
only one case happened occurred after discharge, yielding
an overall morbidity of 0.1%. Considering that only 1.1
stents were used per patient, we mainly attribute the low
risk of paraplegia to the short length of thoracic aorta
covered, as well as avoidance of aortic cross-clamping and
subsequent reperfusion. When sufficient sealing of the
primary entry tear can be achieved, using fewer stents to
avoid long segment coverage can help to decrease the
morbidity of paraplegia.
Insufficient length of the proximal landing zone remains
a challenge for completely excluding the entry tear of the
dissections. There is still a controversy on the safety of
intentional overstenting the LSA.45e47 Our data suggest that
stent graft-induced occlusion of the LSA can be well
tolerated by the majority of patients, with an acceptably
low morbidity of neurological complications and mortality.
In the condition of patent and dominant contralateral
vertebral and a documented intact vertebrobasilar system,
re-vascularisation of the LSA is not required prior to
intentional coverage of the LSA.
Several studies have demonstrated higher in-hospital
mortality and major complication rates for type B-AD
treated with endovascular repair in the acute phase
Table 7 Comparison of acute versus chronic dissection.
Data available (n) p
Acute AD (nZ 356) Chronic AD (nZ 289)
Age (years) 146 50.6 5.2 49 56.2 5.9 0.233
Male gender 146 82.2 0.7% 49 79.6 0.3% 0.685
In-hospital surgical
conversion
356 0% 267 0% ———
Overall complications 117 18.8 2.0% 43 9.3 0.9% 0.149
Major complications 224 0.9 0.3% 206 0% 0.500
Minor complications 102 18.6 1.8% 43 9.3 0.9% 0.160
Procedure-related
complications
184 1.1 0.2% 145 0.7 0.2% 1.000
Retrograde type A-AD 267 0.4 0.1% 218 0% 1.000
Access complications 174 0.6 0.1% 145 0.7 0.2% 1.000
Stroke 194 0% 208 0% ————
Paraplegia 356 0.3 0.1% 267 0% 1.000
30-Day mortality 257 3.1 1.3% 185 2.2 0.2% 0.521a
a Log-rank test.
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status of the patients in the acute phase is considered as
the most important determinant of worse survival.49 The
complicated conditions of rupture and malperfusion are
also important predictors of early mortality.50 These may
explain the worse results in the acute group. In the initial
period, considering the poor anti-hypertensive drug
compliance and low rate of effective hypertension control
in China,51 a few of the stable uncomplicated patients were
treated in the acute phase. This might explain the
comparable outcomes in the acute group with the chronic
group. However, following the current global consensus on
acute type B-AD,52 endovascular repair in China has lately
been strictly reserved for cases complicated with rupture,
malperfusion syndrome and intractable hypertension and
pain. Intensive medical treatment for stable cases should
be emphasised in the future.
Cost-effectiveness is another issue that is of concern.
The most commonly used imported stents in China such as
Talent (Medtronic, USA) and Zenith (Cook, USA) are quite
expensive (about $15 000 per stent) and only a small
proportion of patients in China can afford the cost. In the
past 5 years, several homemade stents such as Hercules &
Aegis (MicroPort, PRC) with a much lower price (about
$7500 per stent) have emerged as an alternative with
encouraging short-term results.15,18,30,36 More homemade
stents will be used to increase the availability of stents for
the relatively poor patients. However, meticulous studies
are warranted to study the long-term complications and
durability of the homemade stents.
As the morbidity of type B-AD is increasing in China,
some demographics different from the European and
American countries, such as a much younger age and sex
ratio, have been observed.53 This indicates that a multi-
centre randomised controlled tests to further study the
endovascular repair for type B-AD in comparison to medical
treatment or traditional surgery are required, and then to
develop a practice guideline that is more adapted to
Chinese patients in the coming years.
Nevertheless, limitations of our study should be pointed
out. It is the selection of patients from observational seriesthat may have a low representation. The relatively low
percentage of studies with data available for some valuable
parameters might further lower the representation and
increase the selection bias. In some articles the definitions
and primary data are ambiguous, which to some degree
impair the statistical power and decrease the reliability of
this study.
Conclusion
In conclusion, our study shows that stent-graft placement
of type B-AD is feasible with high procedure success rate
and acceptably low complication rates. Both early and mid-
term outcomes appear to be encouraging. Reasonably
reducing the number of stent graft used can help to lower
the morbidity of paraplegia. Intentional coverage of the
LSA is safe for extending the short landing zone when
contralateral blood distribution to the brain is sufficient.
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